Polyclonal Antibodies Market to Witness Transformational Changes by 2033

The new report published by The Business Research Company, titled Proton Pump Inhibitors Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the proton pump inhibitors market size has grown steadily in recent years. It will grow from $3.3 billion in 2023 to $3.44 billion in 2024 at a compound annual growth rate (CAGR) of 4.5%. The proton pump inhibitors market size is expected to see steady growth in the next few years. It will grow to $4.12 billion in 2028 at a compound annual growth rate (CAGR) of 4.6%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=10791&type=smp

Rising Incidence Of Gastrointestinal Disorders Fuels Surge In Proton Pump Inhibitors Market
The increasing prevalence of gastrointestinal disorders is expected to drive the growth of the proton pump inhibitors market. Gastrointestinal disorders refer to a collective term of diseases such as nausea, vomiting, food poisoning, and diarrhea that impact the overall biological functioning of the gastrointestinal (GI) tract. Proton pump inhibitors (PPIs) are commonly prescribed as a medication for treating heartburn and acid-related disorders. PPIs reduce the amount of stomach acid made by glands in the stomach lining. The increasing prevalence of gastrointestinal disorders contributes to proton pump inhibitors' growth. For instance, in September 2022, according to Cancer Australia, an Australia-based cancer control group to support cancer patients and raise awareness of the illness, Australia is predicted to see 2,572 new cases of stomach cancer in 2022 (1,661 male cases and 911 female cases). Similarly, in September 2022, according to a survey by the American Gastroenterological Association, a US-based medical association for gastroenterologists with more than 16,000 doctors and scientists as members, due to severe gastrointestinal symptoms, over 40% of Americans have stopped engaging in daily activities in the last year, such as working exercise (19%), finishing tasks (17%), and socializing with friends and family (16%). Therefore, the increasing prevalence of gastrointestinal disorders is expected to propel the growth of the proton pump inhibitors market.

Xiromed's Innovative Entry Launch Of Omeprazole Delayed-Release Capsules Signals Advancements In Proton Pump Inhibitors Market
Product innovation is a key trend gaining popularity in the proton pump inhibitors market. Major companies operating in the proton pump inhibitors market are focused on developing innovative products to strengthen their position and gain a competitive advantage. For instance, in March 2021, Xiromed LLC, a US-based generic division of Insud Pharmaceuticals, launched Omeprazole Delayed-Release Capsules, 20mg, a generic version of Prilosec, used to treat symptoms of gastroesophageal reflux disease (GERD) and other conditions caused by excess stomach acid. Omeprazole is a proton pump inhibitor used to treat gastric acid-related disorders such as gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the over secretion of gastric acid.

The proton pump inhibitors market covered in this report is segmented -

1) By Type: Pantoprazole, Omeprazole, Lansoprazole, Esomeprazole, Rabeprazole, Dexlansoprazole, Other Types
2) By Disease Allocation: Ulcers, Gastroesophageal Reflux Disease, Other Disease Indications
3) By Application: Hospitals, Clinic, Other Applications

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=10791&type=discount

Major companies operating in the proton pump inhibitors market report are AstraZeneca plc, Pfizer Inc., Cadila Pharmaceuticals Limited, Eisai Pharmaceuticals India Pvt. Ltd, Wyeth LLC, Eli Lilly and Company, Bayer AG, Takeda Pharmaceutical Company, Santarus Inc., Janssen Pharmaceuticals, GlaxoSmithKline plc, Changzhou Siyao Pharmaceuticals, Yangzhou Pharmaceutical, Sanofi S.A., Johnson & Johnson, Novartis International AG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd., Zydus Cadila, Glenmark Pharmaceuticals Ltd., Alkem Laboratories Ltd., Cipla Limited, Hetero Drugs Limited, Intas Pharmaceuticals Ltd., Macleods Pharmaceuticals Ltd., Micro Labs Ltd., Natco Pharma Limited, Panacea Biotec Ltd., Strides Pharma Science Limited, Wockhardt Ltd.

Contents of the report:
1. Executive Summary
2. Proton Pump Inhibitors Market Report Structure
3. Proton Pump Inhibitors Market Trends And Strategies
4. Proton Pump Inhibitors Market - Macro Economic Scenario
5. Proton Pump Inhibitors Market Size And Growth
…..
27. Proton Pump Inhibitors Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/proton-pump-inhibitors-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.